Search clinical trials for: AL-335 matching placebo

Total 1334 results

Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants

Healthy

United Kingdom
Karyopharm Therapeutics Inc
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

Endometrial Cancer

United States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Slovakia, Canada, Hungary, Czechia
Sironax USA, Inc.

Completed

A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

Corona Virus Infection

Pakistan, United States, Mexico
The Deutsche Diabetes Forschungsgesellschaft e.V.
Algiax Pharmaceuticals GmbH

Recruiting

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes

Type2 Diabetes

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335

Renal Insufficiency

United States
Alcon Research

Terminated

An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

Adenoviral Conjunctivitis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Venous Thrombosis
University of California, Los Angeles
Massachusetts General Hospital; Washington University School of Medicine; University... and other collaborators

Completed

A Multicenter Study of NAP (AL-108) in Schizophrenia (AL-108)

Schizophrenia

United States
Allon Therapeutics

Completed

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

Mild Cognitive Impairment, So Stated

United States
Alios Biopharma Inc.

Terminated

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Hepatitis C

Belgium
University of California, San Francisco

Completed

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

Progressive Supranuclear Palsy | Corticobasal Degeneration Syndrome | Progressive Nonfluent Aphasia | Predicted Tauopathies, Including | Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17

United States
Alios Biopharma Inc.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Healthy

United Kingdom
Allon Therapeutics

Completed

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Mild Cognitive Impairment

United States, Canada
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Karyopharm Therapeutics Inc

Terminated

Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults

Healthy

Australia
Janssen Research & Development, LLC

Completed

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Hepatitis C, Chronic

Poland, Belgium, Germany, Spain, Canada, Singapore
Syneos Health
Shanghai Novamab Biopharmaceuticals Co. Ltd.

Terminated

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Asthma

Australia
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
Universiti Sains Malaysia

Recruiting

Effect of Low-Level Laser Therapy on Stability During Retention Phase.

Laser Therapy | Orthodontic Retainers

Malaysia
Janssen Research & Development, LLC

Withdrawn

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Hepatic Impairment
Alios Biopharma Inc.
Alexion

Completed

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Chronic Hepatitis C

France
Janssen Research & Development, LLC

Completed

Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants

Healthy

United Kingdom
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
Anji Pharma
Covance

Completed

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

Functional Constipation

China, United States
YSOPIA Bioscience

Completed

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults (CAUSALITY)

Obesity | Metabolic Disease

United States
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Alios Biopharma Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Chronic Hepatitis C

New Zealand, Moldova, Republic of, Mauritius, United Kingdom
Merit E. Cudkowicz, MD
Ra Pharmaceuticals

Completed

HEALEY ALS Platform Trial - Regimen A Zilucoplan

Amyotrophic Lateral Sclerosis

United States
Merit E. Cudkowicz, MD
Biohaven Pharmaceuticals, Inc.

Completed

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Amyotrophic Lateral Sclerosis

United States
New Beta Innovation Limited

Completed

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Terminated

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Pulmonary Arterial Hypertension

Germany, Korea, Republic of, United Kingdom, United States
Beech Tree Labs, Inc.
Norwich Clinical Research Associates Ltd.

Completed

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

Urinary Incontinence

United States
Intercept Pharmaceuticals

Not yet recruiting

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Biliary Atresia
New Beta Innovation Limited

Terminated

YQ23 Study in Patients With Critical Limb Ischaemia (YAN)

Critical Limb Ischemia

Hong Kong
SIMR (Australia) Biotech Pty Ltd.

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

Healthy Volunteers

Australia
Bayer

Completed

A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

Japan
Bayer

Completed

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

Cough

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Schizophrenia

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Belgium, Finland, Netherlands, Serbia, Sweden
Merck Sharp & Dohme LLC

Terminated

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Chronic Hepatitis C
Celldex Therapeutics

Recruiting

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis (EvolvE)

Eosinophilic Esophagitis

United States, Spain, United Kingdom, Canada, Italy, Poland, Australia, Germany
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Alzheimer Disease | Mild Cognitive Impairment

France, Spain, Sweden, Finland
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia

3

Subscribe